🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue

RecruitingPhase 2, Phase 3Ages 40 Years - 60 YearsAllThe University of Hong Kong
NCT06739720 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works. Participants will: * Take 5 capsules once daily for 6 weeks (or wait to start treatment if in waitlist group) * Visit the clinic 2 times for blood tests (before and after taking the supplement) * Complete questionnaires 3 times about their fatigue and quality of life (4 times participants in the waitlist group)

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Meet the Fukuda diagnostic definition of CFS/ME or have persisting fatigue after the infection of SARS-CoV-2 * Are able to complete a 6-week course of intervention; * Able to complete the online validated fatigue surveys. Exclusion Criteria: * Have participated in any type of complements or herbal medicine within the past six months; * Have serious medical conditions that might limit their participation in this intervention; * Diagnosed with acute inflammation; * Are pregnant or are planning a pregnancy in the next 3 months.
💊

What it tests

  • LingZhi capsule
📍

Where

1 site
Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, The University of Hong Kong
Hong Kong, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy